A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Conditions:   Relapsed/Refractory Advanced Solid Tumors;   Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma;   Relapsed/Refractory Myelodysplasia;   Relapsed/Refractory Myelofibrosis Intervention:   Drug: PRT543 Sponsor:   Prelude Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials